ArticleArchives of dermatological research2025
Exploring the effect of hsa-miR-19b-3p on IL-1R1 expression and serum levels in alopecia areata.
Article in Archives of dermatological research, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
1 citing paper in PubMed.
- From mechanisms to therapies: current advances breakthroughs in alopecia areata immunopathology.Frontiers in immunology · 2025Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
5 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Alopecia areata (AA) is an autoimmune condition marked by hair loss, linked to inflammatory processes involving the interleukin-1 receptor type 1 (IL-1R1) pathway. This study aims to explore the relationship between IL-1R1 gene expression, serum IL-1R1 levels, and hsa-miR-19b-3p in relation to AA severity. Using a case-control design, we assessed 100 AA patients and 100 healthy controls, measuring serum IL-1R1 through enzyme-linked immunosorbent assay (ELISA) and analyzing IL-1R1 gene and hsa-miR-19b-3p expression levels via quantitative real-time PCR (qRT-PCR). Bioinformatic analysis predicted a binding site for hsa-miR-19b-3p on the IL-1R1 gene, suggesting a regulatory role for this miRNA in AA pathology. Demonstrated significantly higher serum IL-1R1, IL-1R1 gene expression, and hsa-miR-19b-3p levels in AA patients compared to controls. Within the AA cohort, severe cases showed the highest levels, with notable correlations between serum IL-1R1, IL-1R1 gene expression, and hsa-miR-19b-3p. Receiver Operating Characteristic (ROC) curve analysis revealed robust diagnostic potential, with area under the curve (AUC) values of 0.71, 0.73, and 0.76 for serum IL-1R1, hsa-miR-19b-3p, and IL-1R1 gene expression, respectively. Elevated IL-1R1 and hsa-miR-19b-3p levels are associated with AA and its severity, suggesting these markers have potential as diagnostic and prognostic indicators. These findings enhance the understanding of IL-1R1's role in AA and highlight potential molecular targets for future therapeutic approaches.
Indexed as
Identifiers
39825934What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.